title: Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.
authors.affiliation: Department of Clinical Pharmacology, Flinders University School of Medicine, Finders Drive, Bedford Park, Adelaide, South Australia, 5042, Australia.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Sorich
authors.affiliation: Department of Clinical Pharmacology, Flinders University, Adelaide, Australia.
authors.forename: Andrew
authors.initials: A
authors.lastname: Rowland
authors.affiliation: School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Wiese
references.citation: Clin Pharmacol Ther. 2013 Sep;94(3):376-82
references.pmid: 23670120
references.citation: Clin Cancer Res. 2012 Sep 1;18(17):4526-37
references.pmid: 22733538
references.citation: Atherosclerosis. 2011 Dec;219(2):659-62
references.pmid: 21871624
references.citation: Pharmacoeconomics. 2004;22(8):481-93
references.pmid: 15217305
references.citation: Nat Rev Clin Oncol. 2011 Mar;8(3):171-6
references.pmid: 21364690
references.citation: J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52
references.pmid: 19815849
references.citation: Genet Med. 2009 Jan;11(1):3-14
references.pmid: 18813139
references.citation: PLoS One. 2011;6(12):e28834
references.pmid: 22216121
references.citation: Pharmacoeconomics. 2013 May;31(5):377-91
references.pmid: 23568333
references.citation: PLoS One. 2013 Aug 27;8(8):e72256
references.pmid: 24015225
references.citation: N Engl J Med. 2008 Feb 7;358(6):568-79
references.pmid: 18256392
references.citation: Lancet Oncol. 2012 Oct;13(10):e427-36
references.pmid: 23026828
references.citation: N Engl J Med. 2008 Aug 21;359(8):789-99
references.pmid: 18650507
references.citation: Am Heart J. 2013 Jun;165(6):1008-14
references.pmid: 23708174
references.citation: Eur Heart J. 2012 Sep;33(17):2143-50
references.pmid: 22450429
references.citation: Cleve Clin J Med. 2011 Jun;78(6):393-403
references.pmid: 21632911
references.citation: Public Health Genomics. 2009;12(3):149-57
references.pmid: 19204417
references.citation: N Engl J Med. 2009 Jan 22;360(4):354-62
references.pmid: 19106084
references.citation: J Thromb Haemost. 2010 Aug;8(8):1678-84
references.pmid: 20492467
references.citation: Lancet Oncol. 2012 Jul;13(7):724-33
references.pmid: 22608783
references.citation: Thromb Haemost. 2012 Jul;108(1):199-200
references.pmid: 22552318
references.citation: Lancet. 2000 Mar 25;355(9209):1064-9
references.pmid: 10744093
references.citation: J Clin Oncol. 2013 Mar 20;31(9):1219-30
references.pmid: 23401453
references.citation: Lancet. 2010 Oct 16;376(9749):1320-8
references.pmid: 20801498
references.citation: Clin Pharmacol Ther. 2011 Mar;89(3):348-50
references.pmid: 21326263
references.citation: JAMA. 2011 Dec 28;306(24):2704-14
references.pmid: 22203539
references.citation: Pharmacogenomics. 2011 Jul;12(7):939-51
references.pmid: 21787188
references.citation: Clin Pharmacol Ther. 2013 Feb;93(2):153-8
references.pmid: 23232549
references.citation: N Engl J Med. 2010 Oct 28;363(18):1704-14
references.pmid: 20979470
references.citation: JAMA. 2010 Oct 27;304(16):1821-30
references.pmid: 20978260
references.citation: J Clin Oncol. 2008 Oct 1;26(28):4672-8
references.pmid: 18824714
references.citation: Nat Rev Drug Discov. 2009 Apr;8(4):279-86
references.pmid: 19300459
references.citation: Am Heart J. 2007 Jan;153(1):54-8
references.pmid: 17174637
references.citation: BMJ. 2010 Mar 30;340:c117
references.pmid: 20354011
references.citation: Clin Pharmacol Ther. 2010 Jun;87(6):635-8
references.pmid: 20485318
references.citation: Clin Pharmacol Ther. 2013 Sep;94(3):324-8
references.pmid: 23695185